- Home
- RCEL vs CNTB Comparison
RCEL vs CNTB Comparison
Compare RCEL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- CNTB
- Stock Information
- Founded
- RCEL N/A
- CNTB 2012
- Country
- RCEL United States
- CNTB United States
- Employees
- RCEL N/A
- CNTB N/A
- Industry
- RCEL Medical/Dental Instruments
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- CNTB Health Care
- Exchange
- RCEL Nasdaq
- CNTB Nasdaq
- Market Cap
- RCEL 107.8M
- CNTB 93.9M
- IPO Year
- RCEL N/A
- CNTB 2021
- Fundamental
- Price
- RCEL $3.42
- CNTB $1.66
- Analyst Decision
- RCEL Buy
- CNTB Strong Buy
- Analyst Count
- RCEL 5
- CNTB 3
- Target Price
- RCEL $11.80
- CNTB $8.33
- AVG Volume (30 Days)
- RCEL 260.2K
- CNTB 75.8K
- Earning Date
- RCEL 11-06-2025
- CNTB 11-30-2025
- Dividend Yield
- RCEL N/A
- CNTB N/A
- EPS Growth
- RCEL N/A
- CNTB N/A
- EPS
- RCEL N/A
- CNTB N/A
- Revenue
- RCEL $74,884,000.00
- CNTB $1,965,000.00
- Revenue This Year
- RCEL $20.40
- CNTB N/A
- Revenue Next Year
- RCEL $32.94
- CNTB $453,067.90
- P/E Ratio
- RCEL N/A
- CNTB N/A
- Revenue Growth
- RCEL 38.32
- CNTB N/A
- 52 Week Low
- RCEL $3.37
- CNTB $1.23
- 52 Week High
- RCEL $14.16
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- RCEL 28.06
- CNTB 49.86
- Support Level
- RCEL $3.88
- CNTB $1.57
- Resistance Level
- RCEL $3.91
- CNTB $1.74
- Average True Range (ATR)
- RCEL 0.23
- CNTB 0.12
- MACD
- RCEL -0.05
- CNTB 0.00
- Stochastic Oscillator
- RCEL 0.00
- CNTB 65.62
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.